AI Convergence: Small Molecule Discovery Summit

Cutting-edge AI/ML-driven breakthroughs, including Monte Rosa Therapeutics’ progress in molecular glue degraders, Insilico Medicine’s recent deal with Eli Lilly, the launch of Eli Lilly's TuneLab, coupled with ongoing partnerships between Merck and Variational AI, and Pfizer and XtalPi, are fueling accelerated small molecule innovation. Biopharma are actively pursuing, and investing in, AI/ML approaches that integrate computational and medicinal chemistry insights to re-architect the small molecule discovery funnel.

The inaugural AI Convergence: Small Molecule Discovery Summit arrives at this pivotal juncture to immerse you in the applied learnings needed to catalyze the next wave of AI/ML-powered small molecule development. Delve into AI/ML applications that elucidate undruggable target protein folding, supercharge structure- and ligand-based design, leverage AI/ML-enabled virtual screening to tap into unexplored chemical space, use generative molecular design for molecular glues, covalent inhibitors and degraders, optimize ADME-T, and address data input and federated learning platform opportunities.

Unite with industry leaders such as Insilico Medicine, Psivant Therapeutics, OpenADMET, Sanofi, Novo Nordisk, as well as newcomers including Eli Lilly’s TuneLab, Expedition Medicines and Montai Therapeutics. Expect to explore AI/ML methods, use cases and the convergence of state-of-the-art AI/ML tools, alongside existing approaches, to ignite future AI/ML-enabled small molecule discovery.